Morris has insightful ideas for studying psychedelic toad secretions while prioritizing the conservation of toads.
Environment and diet may play a role in the alkaloid content of secretions from a Brazilian toad species.
Researchers took the psilocybin-making genes from P. cubensis and put them into S. cerevisiae allowing them to produce psilocybin, several of its analogs, and a “new to nature” compound.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Pain was inhibited by an α2-adrenoceptor antagonist and reduced by an α1-adrenoceptor antagonist. Opioid receptors may also be involved in the effects.
Although aeruginascin is only present in psilocybin mushrooms and bufotenidine is present in toads, their structural and chemical similarities may be surprising.
GPCRs play a major role in the psychedelic effect. They also have qualities that make them ideal targets for drug development.
Understanding the potency of the compounds in nature’s cocktails is essential for formulating effective doses.
Severe side effects associated with 5-HT2B agonist drugs have dampened the interest of researchers. The therapeutic potential of psychedelics provides incentive for taking it up again.
Results hint at a possible mechanism for the persistent effect that psilocybin has on mindfulness.